{"filing":{"accession_number":"0001193125-26-269493","cik":"0001422142","ticker":"WHWK","company_name":"Whitehawk Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"whwk-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526269493/whwk-20260611.htm"},"events":[{"id":10804,"run_id":9479,"accession_number":"0001193125-26-269493","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This 8-K Item 5.07 discloses the results of Whitehawk Therapeutics' annual meeting of stockholders held on June 11, 2026, including voting outcomes on three proposals: election of three Class III directors (Behzad Aghazadeh, Richard Maroun, and Emma Reeve), advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent auditor. The detailed vote tallies (For/Against/Withheld/Abstentions/Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7209,"accession_number":"0001193125-26-269493","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Whitehawk Therapeutics' annual meeting of stockholders held on June 11, 2026, including voting outcomes on three proposals: election of three Class III directors (Behzad Aghazadeh, Richard Maroun, and Emma Reeve), advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent auditor. The detailed vote tallies (For/Against/Withheld/Abstentions/Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:18:49.323810+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7209,"accession_number":"0001193125-26-269493","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Whitehawk Therapeutics' annual meeting of stockholders held on June 11, 2026, including voting outcomes on three proposals: election of three Class III directors (Behzad Aghazadeh, Richard Maroun, and Emma Reeve), advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent auditor. The detailed vote tallies (For/Against/Withheld/Abstentions/Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:18:49.323810+00:00","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-06-12"}]}